



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10/K.T.
10/4/01

In re Application of:

KJETIL TASKÉN et al

ELECT.

Appl. No.: 09/428,458

Group Art Unit: 1635

Filed: October 28, 1999

Examiner: Schmidt, M.

For: USE OF IMMUNOMODULATING AGENTS

B

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner
of Patents
Washington, D.C. 20231

RECEIVED
OCT 02 2001
TECH CENTER 1600/2900

Sir:

The Response to Restriction Requirement is in reply to the Office Action dated August 28, 2001, in the above-identified application, for which a response is due on or before September 28, 2001.

The Patent Office is authorized to charge any fees necessary for the continued pendency of the above-identified application to our Deposit Account No. 19-4880.

Accordingly, please amend the above-identified application as follows

IN THE CLAIMS:

Please cancel Claims 25-34 and 36-37.

Please amend the claims as follows:

Claim 22. (Amended) A pharmaceutical composition useful for treating an immunosuppressive disease comprising (A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type Ia isozyme (RI α ₂C₂); and (B) a pharmaceutically acceptable adjuvant or filler.

B¹